| Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture |
2019-04-03 |
| Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion |
2019-04-03 |
| Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital |
2019-04-03 |
| Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital |
2019-04-03 |
| LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program |
2019-04-03 |
| Rave LLC–Bruker Corp: investment, 201904 acquisition €na by Bruker |
2019-04-03 |
| Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer |
2019-04-02 |
| IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for upfront payment + milestones ANNOUNCED |
2019-04-01 |
| Karuna–Alexandria Real Estate: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Alexandria Venture Investments |
2019-04-01 |
| Karuna–ARCH Venture: investment, 201903–201904 financing round Series B totalling $80m incl exisiting + lead investor ARCH Venture Partners |
2019-04-01 |
| Karuna–Eventide Asset Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Eventide |
2019-04-01 |
| Karuna–Fidelity: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Fidelity Management & Research |
2019-04-01 |
| Karuna–Nan Fung: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Pivotal BioVenture Partners |
2019-04-01 |
| Karuna–Partner Fund Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Partner Fund Management |
2019-04-01 |
| Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health |
2019-04-01 |
| Karuna–Sands Capital: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Sands Capital |
2019-04-01 |
| Karuna–SEVERAL: investment, 201903–201904 financing round Series B $80m led by ARCH Venture Partners incl $5m debt conversion |
2019-04-01 |
| Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments |
2019-04-01 |
| Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust |
2019-04-01 |
| Blueprint Medicines–SEVERAL: investment, 201903 public offering $300m+$45m with 4.055m+608k common shares at $74/share |
2019-03-28 |
| Inivata–Consilium: public relations, 201903 service existent by CSC |
2019-03-28 |
| Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors |
2019-03-28 |
| Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA |
2019-03-28 |
| Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA |
2019-03-28 |
| Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners |
2019-03-28 |
| Selvita–Trout Group: public relations, 201903 service existent media relations + IR by The Trout Group |
2019-03-28 |
| Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study |
2019-03-28 |
| H4Orphan Pharma–Cerenis: investment, 201903– excl negotations for potential merger w Cerenis owning 59% of combined company |
2019-03-27 |
| Evotec–Mark Foundation: investment, 201903–202102 research funding for two years €na by Mark Foundation with potential financial returns |
2019-03-26 |
| Brammer Bio–Thermo Fisher: investment, 201903– acquisition $1.7b in cash from Ampersand Capital Partners + Founders ANNOUNCED |
2019-03-24 |
| Hookipa–SEVERAL: investment, 201903– IPO up to $86.3m at Nasdaq FILED |
2019-03-22 |
| Sherlock Biosciences–SEVERAL: investment, 201903 first financing round $35m incl $17.5m grant + an investment from Open Philantrophy Project |
2019-03-21 |
| Verona Pharma–ICR: public relations, 201903 service existent by ICR in US |
2019-03-21 |
| Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai |
2019-03-20 |
| Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) |
2019-03-20 |
| Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares |
2019-03-20 |
| Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen |
2019-03-19 |
| Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares |
2019-03-19 |
| Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp |
2019-03-14 |
| Ovation.io–Borealis Ventures: investment, 201903 financing round Series A totalling $5m incl new + co-investor Borealis Ventures |
2019-03-14 |
| Ovation.io–Madrona Venture: investment, 201903 financing round Series A totalling $5m incl lead investor Madrona Venture Group |
2019-03-14 |
| Ovation.io–SEVERAL: investment, 201903 financing round Series A $5m led by Madrona Venture + incl Borealis Ventures et al. |
2019-03-14 |
| Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications |
2019-03-13 |
| Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri |
2019-03-12 |
| Biogen–Fujifilm: investment, 201903– acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark |
2019-03-12 |
| Osage Partners–SEVERAL: investment, 201903 closing $273m of Osage Univ Partners III LP venture fund |
2019-03-12 |
| Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors |
2019-03-12 |
| AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies |
2019-03-11 |
| InventisBio–Lilly: investment, 201903 financing round Series C totalling $70m incl existing + co-investor Lilly Asia Ventures |
2019-03-11 |
| InventisBio–OrbiMed: investment, 201903 financing round Series C totalling $70m incl existing + co-investor OrbiMed Asia |
2019-03-11 |
| InventisBio–SEVERAL: investment, 201903 financing round Series C $70m co-led by Advantech Capital + CMBI |
2019-03-11 |
| BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m |
2019-03-05 |
| Erasca–Andreessen Horowitz: investment, 201903 financing round Series A extension by $22m to $64m incl new investor Andreessen Horowitz |
2019-03-05 |
| Erasca–ARCH Venture: investment, 201903 financing round Series A extension by $22m to $64m incl new investor ARCH Venture Partners |
2019-03-05 |
| Erasca–Reneo Capital: investment, 201903 financing round Series A extension by $22m to $64m incl new investor Reneo Capital |
2019-03-05 |
| Erasca–SEVERAL: investment, 201903 financing round Series A extension by $22m to $64m incl new investors ARCH + Andreessen Horowitz + Reneo Capital |
2019-03-05 |
| Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs |
2019-03-04 |
| Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED |
2019-03-04 |
| CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility |
2019-03-01 |
| MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation |
2019-02-28 |
| Mersana–SEVERAL: investment, 201902–201903 Public Offering $97.8m with 24.44m shares common stock at $4/share |
2019-02-28 |
| Sarepta Therapeutics–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene |
2019-02-28 |
| CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio |
2019-02-27 |
| Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America |
2019-02-27 |
| Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market |
2019-02-27 |
| MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management |
2019-02-27 |
| MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc |
2019-02-27 |
| MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors |
2019-02-27 |
| MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors |
2019-02-27 |
| MeiraGTx–SEVERAL: investment, 201902 private placement $80m with 5.8m ordinary shares at $13.8/share led by JJDC Inc |
2019-02-27 |
| Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck |
2019-02-27 |
| Hookipa–Invus Group: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Invus |
2019-02-26 |
| Hookipa–Redmile Group: investment, 201902 financing round Series D totalling €33.2m incl new + lead investor Redmile Group |
2019-02-26 |
| Hookipa–Samsara BioCapital: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Samsara BioCapital |
2019-02-26 |
| Hookipa–SEVERAL: investment, 201902 financing round Series D €33.2m ($37.4m) led by Redmile Group + incl Invus + Samsara Capital et al. |
2019-02-26 |
| Samsara Therapeutics–Apollo Ventures: investment, 201902 seed financing round totalling €1m incl lead investor Apollo Ventures |
2019-02-26 |
| Samsara Therapeutics–Evotec: medicinal chemistry, 201902 supply service existent compound optimisationn by Evotec |
2019-02-26 |
| Samsara Therapeutics–SEVERAL: investment, 201902 seed financing round €1m led by Apollo Ventures |
2019-02-26 |
| General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED |
2019-02-25 |
| Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche |
2019-02-25 |
| Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics |
2019-02-25 |
| Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche |
2019-02-25 |
| Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche |
2019-02-25 |
| Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche |
2019-02-25 |
| Spark Therapeutics–Roche: investment, 201902– acquisition $4.3b cash tender offer for all shares at $114.5/share ANNOUNCED |
2019-02-25 |
| AbbVie–Voyager Therapeutics: AAV technology, 201902– collab ww excl $65m upfront +>$1b milestones + royalties developm vectorised Abs for PD |
2019-02-22 |
| Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures |
2019-02-21 |
| Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner |
2019-02-20 |
| BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund |
2019-02-20 |
| BiomX–MacDougall Biomedical Communications: public relations, 201902 service existent by MacDougall |
2019-02-20 |
| BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al |
2019-02-20 |
| Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totallling €20m incl co-lead investor Inkef Capital |
2019-02-20 |
| Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totallling €20m incl co-lead investor Gilde Healthcare |
2019-02-20 |
| Calypso Biotech–JnJ: investment, 201902 financing round Series A totallling €20m incl co-investor JnJ Innovation JJDC |
2019-02-20 |
| Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totallling €20m incl co- + founding investor M Ventures |
2019-02-20 |
| Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital |
2019-02-20 |
| CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies |
2019-02-19 |
| S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch |
2019-02-18 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2018.jpg){kind=logo}
Date![Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px](/banner/iito-20150529-600-080-lsg-life-sciences-germany-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lse-life-sciences-europe-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)